NCT07353931

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 900 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Conditions

• Osteoarthritis
• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	Eloralintide	Administered SC
DRUG	Placebo	Placebo administered SC

Timeline

• Start date: 2026-02-09
• Primary completion: 2028-03-01
• Completion: 2028-05-01
• First posted: 2026-01-21
• Last updated: 2026-04-17

Locations

154 sites across 15 countries: United States, Argentina, Belgium, Brazil, Canada, China, Czechia, Denmark, Germany, Japan, Mexico, Puerto Rico, South Korea, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study